Peripheral arterial disease (PAD) of lower extremity and dyslipidemia

Czech version

Authors: Denisa Čelovská; Viera Štvrtinová; Andrej Dukát
Authors‘ workplace: II. interná klinika LF UK a UN Bratislava
Published in: AtheroRev 2016; 1(3): 138-143
Category: Reviews

Overview

Peripheral arterial disease (PAD) of lower extremity is predominantly a manifestation of atherothrombotic process. Effective cardiovascular (CV) risk treatment is underestimated in clinical practice despite significantly increased cardio-cerbrovascular mortality and morbidity in symptomatic and even in asymptomatic PAD patients. Atherogenic dyslipidemia is a significant risk factor for vascular risk stratification in PAD patients. PAD patients have very high CV risk and the goal level of LDL cholesterol is less than 1.8 mmol/l or even lower according to new studies. First line therapy in PAD patients is statin treatment. However, in not reaching the LDL-cholesterol goal level conveniently, ezitimibe is added. PCSK9 inhibitors are a new perspective in high risk patients and in statin intolerance. What cannot be forgotten is modification of life-style especially in reduction of remnant lipoproteins, which play an important role in peripheral circulation.

Key words:
peripheral arterial disease of lower extremity – dyslipidemia – cardiovascular risk

Sources

1. Štvrtinová V, Štvrtina S. Ischemická bolesť pri periférnom artériovom ochorení končatín. In: Štvrtinová V et al. Bolesť končatín. SAP: Bratislava 2012: 111–132. ISBN 978–80–896027–05–1.

2. Murabito JM, Evans JC, Nieto K et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143(6): 961–965.

3. Fowkes GF, Rudan D, Rudan I et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382(9901): 1329–1340. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(13)61249–0>.

4. Štvrtinová V, Štvrtina S, Wsólová L et al. Prevalence of peripheral arterial disease in the Slovak Republic. CEVJ 2009; 8(1): 32.

5. Criqui MH, Ninomiya J. The epidemiology of peripheral arterial disease. In: Creager M, Dzau VJ, Loscalzo J (eds). Vascular Medicine. 1st ed. Saunders Elsevier: Philadelphia 2006: 223–238.

6. Norgren L, Hiatt WR, Dormandy et al. [TASC II Working Group]. Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007; 45(Suppl): S5-S67.

7. Clement DL, Boccalon H, Dormandy J et al. A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis). Int Angiol 2000; 19(2): 97–125.

8. Alberts MJ, Bhatt DL, Mas JL et al. Three year follow up and event rates in the international Reduction of Atherotrombosis for continued Health registry (REACH). Eur Heart J 2009; 30(19): 2318–2326. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehp355>.

9. Bhatt D, Steg P, Ohman F et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherosclerosis. [REACH registry Investigators]. JAMA 2006; 295(2): 180–189.

10. Češka R, Kvasilová M, Procházková R et al. Hyperlipoproteinémie a dyslipoproteinémie I. Klasifikace, diagnostika, kardiovaskulární, kardiometabolické a reziduálne riziko. Vnitř. Lék 2010; 56(6): 526–531.

11. Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. 2. vyd. Vydavateľstvo UK: Bratislava: 2001. ISBN 80–223–1608–3.

12. Ridker PM, Stampfer M, Rifai N. Novel Risk factors for systematic Atherosclerosis. JAMA 2001; 285(19): 2481–2485.

13. Vrablík M. Hypertriglyceridemický pás a kardiovaskulárni riziko. Interní Medicína pro praxi 2007; 9(12): 552–554. Dostupné z WWW: <http://www.internimedicina.cz/pdfs/int/2007/12/04.pdf>.

14. [Heart Protection Study Collaborative Group]. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7–22.

15. Mohler ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108(12): 1481–1486.

16. Mondillo S, Ballo P, Barbati R et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patinets with peripheral vascular disease. Am J Med 2003; 114(5): 359–364.

17. Štvrtinová V, Šefránek V, Murín J et al. Odporúčania pre diagnostiku a liečbu periférneho artériového ochorenia dolných končatín PAO DK. Vask Med 2010; 2 (52 Suppl): 3–18.

18. Gašpar Ľ, Komorníková A, Gavorník P et al. Liečba kritickej končatinovej ischémie prostaglandínom E1. Vaskulárna medicína 2015; 7(2): 86–88.

19. Nguyen CD, Andersson Ch, Jensen TD et al. Statins treatment and risk of reccurent venous thromboembolism a nationwide cohort study. BMJ Open 2013; 3(11): e 003135. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjopen-2013–003135>.

20. Tendera M, Aboyans V, Bartelink ML et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology(ESC). Eur Heart J 2011; 32(22): 2851–2906. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr211>.

21. Baigent C, Keech A, Kearney PM, et al. Cholesterol treatment Trialists‘ (CTT) Collaborators: Efficacy and safety of cholesterol – lowering tratment: prospective study meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet 2005;366(9493): 1267–1278. Erratum in Lancet 2005; 366(9494):1358. Lancet 2008; 371(9630): 2084.

22. Dukát A. Reziduálne kardiovaskulárne riziko – závažný problém, ktorý si bude vyžadovať nové liečebné prístupy. Cardiology Lett 2008; 17(6): 229–233.

23. Češka R, Votavová L, Aleksičová T. Přelom v léčbe hypercholesterolemie – inhibitory PCSK9. Co zatím víme o alirokumabu (přípravku Praluent). AtheroRev 2016; 1(1): 34–41.

24. Sudhop T, Lütjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption bx ezetimibe in humnas. Circulation 2002; 106(15): 1943–1948.

25. Cannon ChP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therpay after Acute Coronary Syndromes. N Engl J Med 2015; 372(25): 2387–2397. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1410489>.

26. Murín J, Pernický M, Kiňová S. Nové liečebné postupy k dyslipidémii. Cardiology Lett 2014; 23: 197–206.

27. Kumbhani DJ, Steg PG, Cannon CP et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014; 35(41): 2864 -2872. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu080>.

28. Rajamani K, Colman PG, Li LP et al. FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecifi ed analysis of a randomised controlled trial. Lancet 2009; 373(9677): 1780–1788.

29. Wang T, Elam MB, Forbes WP et al. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis 2003; 171(2): 337–342.

30. Vrablík M. Zítřky lipidy modifikující terapie – jaké budou? Kardiol Rev 2012; 14(3): 172–175.

31. Vrablík M, Češka R. Novinky v oblasti hypolipidemické léčby. Vnitř Lék 2014; 60(11): 949–957.

32. Robinson JG, Farnier M, Krempf M et al. Efficacy and Safety of Alirocumab in reducing Lipids and cardiovascular Events. N Engl J Med 2015; 372(16): 1489–1499. Dostupné z DOI: <http://dx.doi.org10.1056/NEJMoa1501031>.

33. Dukát A, Kriška M. Nový prístup v liečbe hyperlipoproteinémií pomocou monoklonálnych protilátok proti proproteínkonvertáze subtilizín/kexín 9 (PCSK9). Int Med 2015; 15(19): 441–443.

34. Franeková J, Jabor A. Markery kardiovaskulárního rizika a jejich použití v běžné, neselektované populaci pacientů. Hypertenze a kardiovaskulární prevence 2012; 1(2): 37–42.

35. Vaverková H, Karásek D. Fosfolipáza A2 asociovaná s lipoproteiny (Lp-PLA2) jako ukazatel aktivity aterosklerózy a potenciální terapeutický cíl. Cor Vasa 2011; 53(4–5): 234–238.

36. Thompson A, Gao P, Orfei L et al. [Lp-PLA2 Studies Collaboration]. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375(9725): 1536–1544. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)60319–4>.

37. Ballanthyne CM, Hoogeveen RC, Bang H, et al. Lp-PLA2, high-sensitivity CRP protein, an risk for incident ischemic stroke in middle-aged men and women in ARIC Study. Arch Intern Med 2005; 165(21): 2479–2484.

38. Tsai AK, Steffen BT, Ordovas JM et al. Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants. Transl Res 2011; 158(2): 99–105. Dostupné z DOI: <http://dx.doi.org/10.1016/j.trsl.2011.01.014>.

Labels

Angiology Diabetology Internal medicine Cardiology General practitioner for adults

Atherogenic dyslipidemia – a new target in cardiovascular prevention

Role of microRNAs in the pathophysiology of atherosclerosis and their potential clinical use

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

What other possibilities of reducing blood pressure we have, apart from antihypertensives

Arterin – a nutritional supplement in the treatment of dyslipidemia: results of a short-term clinical follow-up study

High prevalence of cardiovascular risk factors and inadequate control of LDL cholesterol levels in the population of 40-year old men and 50-year old women in the Czech Republic

Can we improve primary prevention of ischemic heart disease? Which way?

From dyslipidemia to ischemic heart disease and vice versa

Article was published in

Athero Review

2016 Issue 3